Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors

NCT05001282 is registered in ClinicalTrials.gov with Elucida Oncology as lead sponsor.

NCT NCT05001282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05001282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Lead sponsor
Elucida Oncology
Phase
Phase 1/2
Overall status
Terminated
Start date
September 13, 2021
Completion date
June 7, 2024
Enrollment
79 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial adenocarcinoma, endometrial cancer, endometrial cancer recurrent, endometrial carcinosarcoma, endometrial clear cell adenocarcinoma, endometrial diseases, endometrial neoplasms, endometrioid adenocarcinoma, endometrioid tumor, fallopian tube cancer, ovarian adenocarcinoma, ovarian cancer, ovarian cancer recurrent, ovarian cancer stage, ovarian carcinoma, ovarian diseases, ovarian epithelial cancer, ovarian neoplasm epithelial, ovarian neoplasms, ovarian serous adenocarcinoma, ovary cancer, ovary disease, ovary metastasis, ovary neoplasm, peritoneal cancer